AbbVie (NY:ABBV)

These dividend stocks are built for the long haul.

Topics Artificial Intelligence

3 Dividend Stocks to Hold for the Next 20 Years ↗

February 15, 2026

These two stocks have historically zigged when the market has zagged.

Topics Intellectual Property

2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off ↗

February 14, 2026

Topics Stocks

Got $500? 2 Pharma Stocks to Buy and Hold Forever. ↗

February 14, 2026

Growth, value, or both?

As of February 13, 2026, the financial markets are witnessing a historic "Great Rotation," where institutional capital is flowing out of overextended technology valuations and into the defensive,...

AbbVie Inc. (NYSE:ABBV) Raises 2026 Outlook Despite Q4 Revenue Miss ↗

February 04, 2026

Via Chartmill

Gilead Sciences and the 2026 Biotech Resurgence: A Leader in the Great Rotation

February 13, 2026

As of February 12, 2026, the financial landscape has undergone a tectonic shift, with the healthcare sector decisively seizing the mantle of market leadership. After years of dominance by high-flying...

Topics Artificial Intelligence ETFs Government

The Great Rotation: Healthcare Emerges as the S&P 500’s New Crown Jewel in 2026

February 12, 2026

This Dividend King has staying power.

Topics Artificial Intelligence Bonds Economy

1 Reason I'm Never Selling AbbVie Stock ↗

February 12, 2026

As of February 11, 2026, Incyte Corporation (NASDAQ: INCY) finds itself at a pivotal crossroads. Known for over a decade as a one-drug powerhouse centered on the hematology blockbuster Jakafi, the...

Topics Intellectual Property

Incyte (INCY) Deep Dive: Navigating the 2026 Crossroads Following Earnings Miss

February 11, 2026

Via Finterra

Topics Economy Intellectual Property

The 5 Most Interesting Analyst Questions From AbbVie’s Q4 Earnings Call

February 11, 2026

AbbVie’s fourth quarter results came in above Wall Street’s revenue and profit expectations, but the market responded negatively, reflecting concerns over certain business segments and future...

The iShares Core High Dividend ETF is up 12% this year.

Topics Earnings

Silver and Gold Prices Are Volatile. Buy This ETF for Safety This Year ↗

February 10, 2026

EQNX::TICKER_START (NASDAQ:HELP),(NYSE:JNJ),(NYSE:ABBV),(NYSE:TAK),(NYSE:AZN) EQNX::TICKER_END

Topics ETFs

Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market

February 10, 2026

Via FinancialNewsMedia

3 Market-Beating Stocks to Research Further

February 08, 2026

The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends...

The Great Pipeline Grab: Life Sciences Deal Volume Skyrockets 82% as Big Pharma Battles the Patent Cliff

February 06, 2026

The life sciences sector has entered 2026 in the midst of a historic transformation, as deal volume and value surged by a staggering 82% over the past year. This "Great Rebound," fueled by a...

ABBV Q4 Deep Dive: Immunology and Neuroscience Growth Offset Aesthetics Softness and Pricing Headwinds

Topics Artificial Intelligence Economy Intellectual Property

AbbVie’s Prognosis: The February Dip Looks Like a Buy Signal ↗

February 05, 2026

Via MarketBeat

February 05, 2026

Pharmaceutical company AbbVie (NYSE:ABBV) missed Wall Street’s revenue expectations in Q4 CY2025, but sales rose 6% year on year to $16 billion. Its non-GAAP profit of $2.71 per share was 2.2% above...

AbbVie (ABBV) Q4 2025 Earnings Call Transcript

AbbVie (ABBV) Q4 2025 Earnings Call Transcript ↗

February 04, 2026

Stay updated with the S&P500 stocks that are on the move in today's pre-market session. ↗

Topics Earnings

Gapping S&P500 stocks in Wednesday's session ↗

February 04, 2026

Via Chartmill

February 04, 2026

Via Chartmill

AbbVie’s (NYSE:ABBV) Q4 CY2025: Beats On Revenue

February 04, 2026

Pharmaceutical company AbbVie (NYSE:ABBV) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 10% year on year to $16.62 billion. Its non-GAAP profit of $2.71 per...

AbbVie and Medtronic have a long history of raising their dividends and continue to have healthy free cash flow for further dividend growth.

2 Healthcare Dividend Stocks That are Just What the Doctor Ordered ↗

February 03, 2026

Pharmaceutical company AbbVie (NYSE:ABBV) will be reporting earnings this Wednesday before market open. Here’s what to expect.

Topics Intellectual Property

AbbVie (ABBV) Q4 Earnings: What To Expect

February 02, 2026

The high-stakes world of biotechnology faced a jarring reality check on January 26, 2026, as shares of Revolution Medicines (Nasdaq: RVMD) cratered by 17%. The sharp decline came as the speculative...

The Sound of Silence: Revolution Medicines Plummets 17% as M&A Hopes Evaporate

February 02, 2026

A prediction for AbbVie in 2031: The drugmaker will be bigger and kinglier.

Topics ETFs Government Initial Public Offering

Where Will AbbVie Be in 5 Years? ↗

February 02, 2026

They are great long-term options.

Topics Intellectual Property

2 No-Brainer Dividend Stocks to Buy Hand Over Fist ↗

February 01, 2026

The choice between the two might come down to each investor's goals and risk tolerance.

Topics Economy Intellectual Property

Better Long-Term Buy: This Emerging Player or the Industry Leader? ↗

January 30, 2026

As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including AbbVie (NYSE:ABBV) and its peers.

Topics Intellectual Property

Q3 Earnings Highs And Lows: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks

January 28, 2026

The company sure knows what to do before and after a blockbuster drug tumbles off the patent cliff.

Topics Artificial Intelligence

Why AbbVie Stock Trounced the Market in 2025 ↗

January 28, 2026

Eli Lilly Reinforces Immunology Dominance with $1.2 Billion Acquisition of Ventyx Biosciences

Topics Intellectual Property

January 27, 2026

In a decisive move to solidify its leadership in the next generation of chronic inflammation and cardiometabolic treatments, Eli Lilly and Company (NYSE: LLY) announced the acquisition of Ventyx...

It doesn't look like the company will end up in the arms of an acquirer soon, after all.

Why Revolution Medicines Stock Plummeted by Almost 17% Today ↗

January 26, 2026